Filtered By:
Specialty: Cancer & Oncology
Cancer: HER2

This page shows you your search results in order of date.

Order by Relevance | Date

Total 124 results found since Jan 2013.

S100A9 promotes glycolytic activity in HER2-positive breast cancer to induce immunosuppression in the tumour microenvironment
CONCLUSIONS: S100A9 overexpression upregulated the glycolysis activity of tumour cells through the c-Myc-related pathway, suppressing lymphocyte infiltration in the tumour stroma, affecting the efficacy of immune regulation and long-term survival of patients.PMID:36755606 | PMC:PMC9900376 | DOI:10.1016/j.heliyon.2023.e13294
Source: Cancer Control - February 9, 2023 Category: Cancer & Oncology Authors: Jia-Qi Yuan Shou-Man Wang Lei Guo Source Type: research

Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth
CONCLUSIONS: Our results indicate that EDI3 may be a potential novel therapeutic target in patients with HER2-targeted therapy-resistant ER-HER2 + breast cancer that should be further explored.PMID:36670508 | DOI:10.1186/s13046-022-02578-w
Source: Clinical Genitourinary Cancer - January 20, 2023 Category: Cancer & Oncology Authors: Magdalena Keller Katharina Rohlf Annika Glotzbach Gregor Leonhardt Simon L üke Katharina Derksen Özlem Demirci Defne G öçener Mohammad AlWahsh J örg Lambert Cecilia Lindskog Marcus Schmidt Walburgis Brenner Matthias Baumann Eldar Zent Mia-Lisa Zischi Source Type: research

Combination of Nanovectorized siRNA Directed against Survivin with Doxorubicin for Efficient Anti-Cancer Activity in HER2+ Breast Cancer Cells
In conclusion, a combination of anti-Survivin siRNA and DOX would be a good alternative in HER2+ breast cancer therapy.PMID:36432729 | DOI:10.3390/pharmaceutics14112537
Source: Cancer Control - November 26, 2022 Category: Cancer & Oncology Authors: Sahar Eljack Emilie Allard-Vannier Yoann Misericordia Katel Herv é-Aubert Nicolas Aubrey Igor Chourpa Areeg Faggad Stephanie David Source Type: research

Overcoming the non-kinetic activity of EGFR1 using multi-functionalized mesoporous silica nanocarrier for in vitro delivery of siRNA
Sci Rep. 2022 Oct 14;12(1):17208. doi: 10.1038/s41598-022-21601-w.ABSTRACTTriple-negative breast cancer (TNBC) does not respond to HER2-targeted and hormone-based medicines. Epidermal growth factor receptor 1 (EGFR1) is commonly overexpressed in up to 70% of TNBC cases, so targeting cancer cells via this receptor could emerge as a favored modality for TNBC therapy due to its target specificity. The development of mesoporous silica nanoparticles (MSNs) as carriers for siRNAs remains a rapidly growing area of research. For this purpose, a multi-functionalized KIT-6 containing the guanidinium ionic liquid (GuIL), PEI and PEGy...
Source: Cancer Control - October 14, 2022 Category: Cancer & Oncology Authors: Javad Parnian Leila Ma'mani Mohamad Reza Bakhtiari Maliheh Safavi Source Type: research

Cancers, Vol. 14, Pages 4496: Ceramide Kinase (CERK) Emerges as a Common Therapeutic Target for Triple Positive and Triple Negative Breast Cancer Cells
jjaini Dasgupta Sphingolipids are key signaling biomolecules that play a distinct role in cell proliferation, migration, invasion, drug resistance, metastasis, and apoptosis. Triple-negative (ER-PR-HER2-) and triple-positive (ER+PR+HER2+) breast cancer (called TNBC and TPBC, respectively) subtypes reveal distinct phenotypic characteristics and responses to therapy. Here, we present the sphingolipid profiles of BT-474 and MDA-MB-231 breast cancer cell lines representing the TPBC and TNBC subtypes. We correlated the level of different classes of sphingolipids and the expression of their corresponding metabolizing enzymes...
Source: Cancers - September 16, 2022 Category: Cancer & Oncology Authors: Kajal Rajput Mohammad Nafees Ansari Somesh K. Jha Trishna Pani Nihal Medatwal Somdeb Chattopadhyay Avinash Bajaj Ujjaini Dasgupta Tags: Article Source Type: research

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
CONCLUSIONS: Our study shows that CRC resistance to EGFR inhibitors results primarily from the inability of the inhibitors to downregulate their target and that a PEPDG278D-based combination treatment overcomes the resistance.PMID:35650607 | DOI:10.1186/s13046-022-02389-z
Source: Clinical Colorectal Cancer - June 1, 2022 Category: Cancer & Oncology Authors: Lu Yang Arup Bhattacharya Yun Li Sandra Sexton Xiang Ling Fengzhi Li Yuesheng Zhang Source Type: research

Human Tumor Targeted Cytotoxic Mast Cells for Cancer Immunotherapy
The diversity of autologous cells being used and investigated for cancer therapy continues to increase. Mast cells (MCs) are tissue cells that contain a unique set of anti-cancer mediators and are found in and around tumors. We sought to exploit the anti-tumor mediators in MC granules to selectively target them to tumor cells using tumor specific immunoglobin E (IgE) and controllably trigger release of anti-tumor mediators upon tumor cell engagement. We used a human HER2/neu-specific IgE to arm human MCs through the high affinity IgE receptor (FcεRI). The ability of MCs to bind to and induce apoptosis of HER2/neu-positive...
Source: Frontiers in Oncology - April 22, 2022 Category: Cancer & Oncology Source Type: research

Polymorphisms of an oncogenic gene, mesothelin, predict the risk and prognosis of gastric cancer in a Chinese Han population
This study aims to explore the biological function of MSLN in gastric cancer and to evaluate the association of MSLN polymorphism (rs3764247, rs3764246, rs12597489, rs1057147, rs3765319) with the risk and prognosis of gastric cancer. Small interfering RNA (siRNA) transfection and MSLN overexpression were performed in human gastric cancer cell lines, respectively. The proliferation of tumor cells was evaluated by Cell counting kit 8(CCK-8) and colony formation assay. Wound healing assay and transwell assay were used to elucidate gastric cancer cell migration and invasion rates. We conducted a case-control study involving 86...
Source: Cancer Control - April 9, 2022 Category: Cancer & Oncology Authors: Kuan Shen Kanghui Liu Yuanhang Wang Peidong Ni Jian Xiao Fan Hao Xinyi Zhou Zekuan Xu Li Yang Source Type: research

Investigation of Candidate Genes and Pathways in Basal/TNBC Patients by Integrated Analysis
CONCLUSION: The DEGs and their enriched functions and pathways identified in this study contribute to the understanding of the molecular mechanisms of TNBC. In addition, FOXD1, DLL3, and LY6D may be defined as the prognostic markers and potential therapeutic targets for TNBC patients.PMID:34184566 | DOI:10.1177/15330338211019506
Source: Technology in Cancer Research and Treatment - June 29, 2021 Category: Cancer & Oncology Authors: Qi Liu Xiang Song Zhaoyun Liu Zhiyong Yu Source Type: research

Cancers, Vol. 13, Pages 2318: Syndecan-1 Promotes Angiogenesis in Triple-Negative Breast Cancer through the Prognostically Relevant Tissue Factor Pathway and Additional Angiogenic Routes
im Martin Götte Triple-negative breast cancer (TNBC) is characterized by increased angiogenesis, metastasis, and poor survival. Dysregulation of the cell surface heparan sulfate proteoglycan and signaling co-receptor Syndecan-1 is linked to poor prognosis. To study its role in angiogenesis, we silenced Syndecan-1 in TNBC cell lines using a 3D human umbilical vein endothelial cell (HUVEC) co-culture system. Syndecan-1 siRNA depletion in SUM-149, MDA-MB-468, and MDA-MB-231 cells decreased HUVEC tubule network formation. Angiogenesis array revealed reduced VEGF-A and tissue factor (TF) in the Syndecan-1-silenced secret...
Source: Cancers - May 12, 2021 Category: Cancer & Oncology Authors: Eyyad Nassar Nourhan Hassan Eslam A. El-Ghonaimy Hebatallah Hassan Mahmoud Salah Abdullah Theresa V. Rottke Ludwig Kiesel Burkhard Greve Sherif Abdelaziz Ibrahim Martin G ötte Tags: Article Source Type: research

Discovery and Pharmacological Evaluation of STEAP4 as a Novel Target for HER2 Overexpressing Breast Cancer
In conclusion, STEAP4 may represent a novel BC related biomarker and a potential pharmacological target for the treatment of HER2 overexpressing BC.
Source: Frontiers in Oncology - March 26, 2021 Category: Cancer & Oncology Source Type: research

Cancers, Vol. 13, Pages 922: Detection of Tumor-Associated Membrane Receptors on Extracellular Vesicles from Non-Small Cell Lung Cancer Patients via Immuno-PCR
Eriksson Karlström Precision cancer medicine for non-small-cell lung cancer (NSCLC) has increased patient survival. Nevertheless, targeted agents towards tumor-associated membrane receptors only result in partial remission for a limited time, calling for approaches which allow longitudinal treatment monitoring. Rebiopsy of tumors in the lung is challenging, and metastatic lesions may have heterogeneous signaling. One way ahead is to use liquid biopsies such as circulating tumor DNA or small extracellular vesicles (sEVs) secreted by the tumor into blood or other body fluids. Herein, an immuno-PCR-based detection of the...
Source: Cancers - February 22, 2021 Category: Cancer & Oncology Authors: Christiane Stiller Kristina Viktorsson Elizabeth Paz Gomero Petra H ååg Vasiliki Arapi Vitaliy O. Kaminskyy Caroline Kamali Luigi De Petris Simon Ekman Rolf Lewensohn Amelie Eriksson Karlstr öm Tags: Article Source Type: research

A Combined Bioinformatic and Nanoparticle-Based Study Reveal the Role of ABCG2 in the Resistance of Breast Cancer.
CONCLUSION: Our findings provide a more in-depth understanding of ABCG2 as a biomarker for predicting DOX-resistance and insights into the development of related therapeutic targets in breast cancer. PMID: 33602075 [PubMed - as supplied by publisher]
Source: Recent Patents on Anti-Cancer Drug Discovery - February 21, 2021 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Cancers, Vol. 13, Pages 80: The ITIM-Containing Receptor: Leukocyte-Associated Immunoglobulin-Like Receptor-1 (LAIR-1) Modulates Immune Response and Confers Poor Prognosis in Invasive Breast Carcinoma
Conclusion: High expression of LAIR-1 is associated with poor clinical outcome in BC. Association with immune cells and immune checkpoint markers warrant further studies to assess the underlying mechanistic roles.
Source: Cancers - December 30, 2020 Category: Cancer & Oncology Authors: Chitra Joseph Mansour A. Alsaleem Michael S. Toss Yousif A. Kariri Maryam Althobiti Sami Alsaeed Abrar I. Aljohani Pavan L. Narasimha Nigel P. Mongan Andrew R. Green Emad A. Rakha Tags: Article Source Type: research